Curium Pharma has been awarded a macro contract in Andalusia, Spain. The pharmaceutical company has been awarded a $57,1 million (€52.3 million) contract to supply radiopharmaceuticals to the Andalusian Health Service (SAS) centers over the next 48 months. The company will also be responsible for the maintenance of the equipment dedicated to nuclear medicine treatments and the management of the waste generated.
The regional executive justified the contract by stating that “the SAS must have radiopharmaceuticals in conditions to be administered to patients who need them.” The Andalusian government points out that “radiopharmaceuticals have the legal status of special medicines and the facilities where they are handled are subject to very strict legislation on nuclear safety; their application can only be carried out in the nuclear medicine services or units of hospitals.”
Breaking news from the biotech, clinical research, and pharmaceutical industries. Born2Invest mobile app is the home of the life sciences industry. Read the latest biotechnology articles on biotech industry leaders, emerging biotech companies, financial headlines, and other biotech industry news.
Curium Pharma, a major player in medicine
Curium Pharma was born from the merger of two world giants in nuclear medicine: the American IBA Molecular and the Irish Mallinckrodt. The European company, named after scientists Marie and Pierre Curie, treats fourteen million patients a year in more than sixty countries. It has a portfolio of more than 6,000 clients and employs 2,000 qualified professionals.
Drawing on over 100 years of experience, Curium combines proven heritage with a pioneering approach to deliver innovation, excellence and unparalleled service. Known as the world’s leading provider of nuclear medicine, Curium has a single focus – to develop, manufacture and supply world-class radiopharmaceutical products to customers around the globe.
Similarly, Curium has a portfolio of 50 products that are produced in three manufacturing plants and distributed through 44 nuclear pharmacies in the U.S. and Europe. The company’s headquarters are located in London, Paris, St. Louis (USA) and Luxembourg. In Spain, its headquarters are located in Alcobendas, Madrid. The company has been awarded the contract to supply radiopharmaceuticals to other administrations in addition to Andalusia. In Madrid, the company is responsible for supplying this type of medication to the Gregorio Maranon University Hospitals.
Curium made the news in February 2019 because the National Commission of Markets and Competition (CNMC) opened a sanctioning procedure against the company for possible restrictive practices in the production and commercialization of radiopharmaceuticals. The commission accused Curium Pharma of making a pact with Advanced Accelerator Applications Ibérica to share the market, set prices and exchange information.
Radiopharmaceuticals, an unstable medication
Radiopharmaceuticals have a number of characteristics that make them different from other conventional drugs. This type of product emits radioactivity and undergoes radioactive degradation, so its composition varies relatively quickly and has a very short effective half-life.
These characteristics require special management of the waste they generate. “From the preparation to the administration to the patient, waste materials, containers, equipment or instruments contaminated with radiation are produced, which is biohazardous and must be treated scrupulously so as not to cause accidental damage,” stated the Andalusian Government in the tender report.
For this reason, the contract requires that the company that won the tender, which in this case is Curium, is also responsible for the waste disposal function. Similarly, it must be responsible for sending the material to hospitals safely.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantDoce., a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Community Foundation Raises Money for Flood Victims in Como, Italy
The flood that hit Como has made headlines. The Community Foundation is now raising funds to help people affected. The...
The Fintech Sector in Argentina Now in the Spotlight: New Security Standards for e-Wallets
ABA and Adeba, two chambers of private banks, asked the Central Bank for greater controls and regulations for fintech companies...
The First Medical Cannabis Agricultural Cooperative in Argentina
While at national level the Law of Productive Cannabis is being debated, which will promote the constitution of Cooperatives that...
Enerbrain Collects €5.2 Million from EDF, Equiter and Azimut Digitech Fund
The investment round comes after a record year for Enerbrain, which has seen its revenues grow by more than 300%...
Buffett Made This One Big Mistake. Don’t Let Yourself Do the Same
When an investment opportunity like AR and VR comes along, it can be hard knowing when to jump. Even if...
Business6 days ago
Forget Facebook (NASDAQ: FB) and Apple (NASDAQ: AAPL): Virtual Reality (VR) and Augmented Reality (AR) Investors Should Snap Up XRApplied (CSE: XRA) Instead
Business7 days ago
What Artificial Intelligence Means for Us Today?
Cannabis6 days ago
El Cesar has the Conditions to Enter the Medical Cannabis Market in Colombia
Crowdfunding7 days ago
Four Million Round for the Italian Real Estate Crowdfunding Portal Walliance